[|Since psoriasis is a polygenic disease, it cannot be the outcome of a
single cell anomaly – again, here I disagree strongly.|auteur195]
[|I strongly support the statement "psoriasis
is the outcome of a skin cell anomaly". Indeed, we cannot consider psoriasis a
defect in one cell type. Although T-cells have received a lot of attention, it
is intriguing that anti-TNFa
treatments are more effective as compared to T-cell specific approaches. It is
the broad interaction of TNF-a which
proves to be essential for a substantial therapeutic effect, whilst T-cell
targeted treatments have a more modest efficacy.|auteur197]
It has been clearly demonstrated for over 30 years now, particularly by Gerald Krueger, that grafting lesional or non lesional psoriatic skin onto a nude mouse ends in maintaining a psoriatic phenotype in the form of persistent epidermal hyperproliferation, when comparing these grafts with normal skin grafts. This epidermal hyperproliferation is only produced if the dermis is also grafted, indicating that dermal cells are necessary for the expression of a psoriatic phenotype. More recently, it has been shown that activated T lymphocytes from a psoriasis plaque, when injected into a psoriatic skin grafted onto a nude mouse, led to the appearance of a clinical and histological psoriasis plaque. By contrast, injecting these same cells into normal skin grafted onto the nude mouse does not have this effect. The inflammatory cells, therefore, only cause psoriasis to appear if they encounter abnormal skin cells.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.
Bioorg. Med. Chem. Lett..
2020 Aug 15, 30, (16):127298.
We report on the discovery of the new clinical candidate BAY 1003803 as glucocorticoid receptor agonist for the topical treatment of psoriasis or severe atopic dermatitis. In the course of optimizing the amino alcohol series as a highly potent new non-steroidal lead structure, considerations were made as to how physicochemical properties and safety concerns relate to structural motifs. BAY 1003803 demonstrates strong anti-inflammatory activity in vitro paired with a pharmacokinetic profile (...)
see on pubmed
Immobilization of papain enzyme on a hybrid support containing zinc oxide nanoparticles and chitosan for clinical applications.
Carbohydr Polym.
2020 Sep 01, 243:116498.
A new hybrid bionanomaterial composed of zinc oxide nanoparticles (ZnO NPs) and chitosan was constructed after enzymatic immobilization of papain for biomedical applications. In this work, we report the preparation and characterization steps of this bionanomaterial and its biocompatibility in vitro. The properties of the immobilized papain system were investigated by transmission electron microscopy, zeta potential, DLS, UV-vis absorption spectroscopy, FTIR spectroscopy, and X-ray (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
on Atopic Dermatitis
Diagnostic Models for Atopic Dermatitis Based on Serum Microbial Extracellular Vesicle Metagenomic Analysis: A Pilot Study.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):792-805.
Associations between a wide variety of diseases and the microbiome have been extensively verified. Recently, there has been a rising interest in the role the microbiome plays in atopic dermatitis (AD). Furthermore, metagenomic analysis of microbe-derived extracellular vesicles (EVs) has revealed the importance and relevance of microbial EVs in human health.
see on pubmed
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Jang H et al.
Mitochondrial and Nuclear Mitochondrial Variants in Allergic Diseases.
Allergy Asthma Immunol Res.
2020 Sep , 12, (5):877-884.
The mitochondrial genome encodes core catalytic peptides that affect major metabolic processes within a cell. Here, we investigated the association between mitochondrial DNA (mtDNA) variants and allergic diseases, including atopic dermatitis (AD) and asthma, alongside heteroplasmy within the mtDNA in subjects with allergic sensitization. We collected genotype data from 973 subjects with allergic sensitization, consisting of 632 children with AD, 498 children with asthma, and 481 healthy (...)
see on pubmed
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
